Sort
51,593 grants matching “hepatitis”
New Approaches to the Evaluation and Treatment of Acromegaly
$585,608Pamela U Freda · Columbia University Health Sciences · R01 · FY2020 · DK
New Approaches to the Evaluation and Treatment of Acromegaly
$585,608Pamela U Freda · Columbia University Health Sciences · R01 · FY2019 · DK
3/3 COMpAAAS Tripartite: ART-CC, KP, and VA
$585,586Amy Caroline Justice · Yale University · U01 · FY2019 · AA
Role of NgBR in regulating hepatic gluconeogenesis and insulin resistance
$585,581Qing Miao · Nyu Long Island School Of Medicine · R01 · FY2022 · DK
Liver Disease and HIV-HBV Coinfection in the HAART era
$585,502Johns Hopkins University · R01 · FY2005 · AI
Prevention of Pediatric NAFLD in Hispanic Children
$585,432Miriam B. Vos · Emory University · R01 · FY2022 · NR
Rescue of Hemostasis-deficiency States
$585,414Elliot David Rosen · University Of Notre Dame · P01 · FY2008 · HL
Safety and Effectiveness of Medications for Alcohol Use Disorder among HIV+/-
$585,332E. Jennifer Edelman · Yale University · P01 · FY2024 · AA
STUDY FOR THE TREATMENT OF REFRACTORY ASCITES
$585,301Virginia Commonwealth University · R01 · FY2000 · DK
Brain Circuits Involved in the Sympathetic Control of the Liver
$585,290Andrea Zsombok · Tulane University Of Louisiana · R01 · FY2020 · DK
CVD in American Indians Genetics Center
$585,278Shelley A Cole · Texas Biomedical Research Institute · R01 · FY2014 · HL
Altered Hepatic Disposition of Anionic Drugs-Mechanisms
$585,275Kim L Brouwer · Univ Of North Carolina Chapel Hill · R01 · FY2016 · GM
Integrative Physiology of Thyroid Hormone Receptors and Nuclear Receptor Corepressors
$585,267Mitchell A. Lazar · University Of Pennsylvania · R01 · FY2024 · DK
Integrative Physiology of Thyroid Hormone Receptors and Nuclear Receptor Corepressors
$585,267Mitchell A. Lazar · University Of Pennsylvania · R01 · FY2025 · DK
Biochemical and Genetic Markers of Type 2 Diabetes Risk
$585,262Frank B Hu · Brigham And Women'S Hospital · R01 · FY2013 · DK
IGF::OT::IGF ANALYSIS OF CHEMICAL STRUCTURES AND THERAPEUTIC ACTIVITY OF AGENTS FOR HIV AND TUBERCULOSIS (CHEMDB)
$585,077Rocco Casagrande · Gryphon Scientific, Llc · N01 · FY2016 · AI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC
$585,065Michael R Green · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · CA
Health Promotion Coaching/Vaccine for Homeless Parolees
$585,046Adeline M Nyamathi · University Of California Los Angeles · R01 · FY2013 · DA
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$585,015Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2022 · CA
Homeostatic Role of IRE1a-XBP1-PDI1 in Hepatic Lipid Metabolism
$585,000Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2019 · DK
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
$585,000Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2017 · DK
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
$585,000Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2015 · DK
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
$585,000Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2016 · DK
Homeostatic role of IRE1a-XBP1-PDI1 in hepatic lipid metabolism
$585,000Randal J. Kaufman · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2018 · DK
Continuum of Care for Drug-Involved Offenders
$584,962Peter D. Friedmann · Rhode Island Hospital · U01 · FY2011 · DA